Mainstay Medical announces half year financial results
Dublin, Ireland: 28 August 2014 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE) announces its results for the six month period ended 30 June 2014. Mainstay is an Irish medical device company with operations in Ireland, Australia and the United States. The Company is focused on the development and commercialisation of ReActiv8, an innovative implantable neurostimulation device designed to treat people with Chronic Low Back Pain (CLBP) by helping to restore control to the muscles that stabilise the lumbar spine.
Next > NGDATA named a 2014 Ventana Research Technology Innovation Award Winner
Previous > Nexstim progresses its navigated brain stimulation technology in stroke and demonstrates improved outcomes in brain tumor surgery